newsfilter
← Latest News
Business Wire·

Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851

Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that the first patient has been dosed in a Phase 2 expansion cohort study